PLoS One:免疫逃逸基因在葡萄膜黑色素瘤中的差异调节和预后表征

2019-01-31 MedSci MedSci原创

意大利卡塔尼亚大学生物医学与生物技术科学系的Basile MS和眼科的Russo A等人近日在PLoS One杂志上发表了一篇重要的工作。葡萄膜黑色素瘤(UM)是成人中最常见的原发性眼内癌症。在该项研究中,作者旨在描述原发性UM癌症的免疫学特征,并对预后标志物和治疗结果进行关联分析。此外,他们评估了微环境对UM中抑制性免疫检查点表达的影响。感兴趣的基因包括MHC I类和II类分子以及抑制性免疫检查

意大利卡塔尼亚大学生物医学与生物技术科学系的Basile MS和眼科的Russo A等人近日在PLoS One杂志上发表了一篇重要的工作。葡萄膜黑色素瘤(UM)是成人中最常见的原发性眼内癌症。在该项研究中,作者旨在描述原发性UM癌症的免疫学特征,并对预后标志物和治疗结果进行关联分析。此外,他们评估了微环境对UM中抑制性免疫检查点表达的影响。感兴趣的基因包括MHC I类和II类分子以及抑制性免疫检查点,即PDL1、PDL2、B7-H3、B7-H4、TBFRSF6B、CD47、CD155、GAL9、HVEM和CD200。

与正常葡萄膜黑素细胞相比,他们观察到在UM细胞中,MHC基因的表达水平显着降低。然而,出乎意料的是,与正常黑素细胞相比,在癌细胞中,分析的大多数抑制性免疫检查点基因的表达水平没有差异,只有CD200和HVEM的表达水平显着降低。另一方面,PDL1与OS、PFS和肿瘤厚度之间存在负相关。此外,在炎性条件下,PDL1与PDL2的表达显着增加。最后,他们首次提出,CD47可能在UM的免疫逃避中具有特异性作用。

总之,他们在该研究中显示,CD47在炎症刺激后被UM细胞显着上调,它可以作为疾病进展的良好独立预测因子。此外,该研究的结果可能推动UM患者的免疫疗法发展。

原文出处:

Basile, M.S., et al., Differential modulation and prognostic values of immune-escape genes in uveal melanoma. PLoS One, 2019. 14(1): p. e0210276.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1820058, encodeId=cb11182005884, content=<a href='/topic/show?id=f073100199b2' target=_blank style='color:#2F92EE;'>#预后表征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100199, encryptionId=f073100199b2, topicName=预后表征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e2c339, createdName=by2009, createdTime=Thu Nov 07 13:03:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680594, encodeId=b9e91680594e1, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Sep 16 18:03:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1790323, encodeId=d0481e9032378, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sun Mar 17 02:03:00 CST 2019, time=2019-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425947, encodeId=fc27142594e1a, content=<a href='/topic/show?id=588988285e6' target=_blank style='color:#2F92EE;'>#葡萄膜黑色素瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88285, encryptionId=588988285e6, topicName=葡萄膜黑色素瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Feb 02 03:03:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558952, encodeId=2d841558952bc, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Feb 02 03:03:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564961, encodeId=6e1f15649616f, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Feb 02 03:03:00 CST 2019, time=2019-02-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1820058, encodeId=cb11182005884, content=<a href='/topic/show?id=f073100199b2' target=_blank style='color:#2F92EE;'>#预后表征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100199, encryptionId=f073100199b2, topicName=预后表征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e2c339, createdName=by2009, createdTime=Thu Nov 07 13:03:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680594, encodeId=b9e91680594e1, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Sep 16 18:03:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1790323, encodeId=d0481e9032378, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sun Mar 17 02:03:00 CST 2019, time=2019-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425947, encodeId=fc27142594e1a, content=<a href='/topic/show?id=588988285e6' target=_blank style='color:#2F92EE;'>#葡萄膜黑色素瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88285, encryptionId=588988285e6, topicName=葡萄膜黑色素瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Feb 02 03:03:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558952, encodeId=2d841558952bc, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Feb 02 03:03:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564961, encodeId=6e1f15649616f, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Feb 02 03:03:00 CST 2019, time=2019-02-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1820058, encodeId=cb11182005884, content=<a href='/topic/show?id=f073100199b2' target=_blank style='color:#2F92EE;'>#预后表征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100199, encryptionId=f073100199b2, topicName=预后表征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e2c339, createdName=by2009, createdTime=Thu Nov 07 13:03:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680594, encodeId=b9e91680594e1, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Sep 16 18:03:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1790323, encodeId=d0481e9032378, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sun Mar 17 02:03:00 CST 2019, time=2019-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425947, encodeId=fc27142594e1a, content=<a href='/topic/show?id=588988285e6' target=_blank style='color:#2F92EE;'>#葡萄膜黑色素瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88285, encryptionId=588988285e6, topicName=葡萄膜黑色素瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Feb 02 03:03:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558952, encodeId=2d841558952bc, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Feb 02 03:03:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564961, encodeId=6e1f15649616f, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Feb 02 03:03:00 CST 2019, time=2019-02-02, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1820058, encodeId=cb11182005884, content=<a href='/topic/show?id=f073100199b2' target=_blank style='color:#2F92EE;'>#预后表征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100199, encryptionId=f073100199b2, topicName=预后表征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e2c339, createdName=by2009, createdTime=Thu Nov 07 13:03:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680594, encodeId=b9e91680594e1, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Sep 16 18:03:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1790323, encodeId=d0481e9032378, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sun Mar 17 02:03:00 CST 2019, time=2019-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425947, encodeId=fc27142594e1a, content=<a href='/topic/show?id=588988285e6' target=_blank style='color:#2F92EE;'>#葡萄膜黑色素瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88285, encryptionId=588988285e6, topicName=葡萄膜黑色素瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Feb 02 03:03:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558952, encodeId=2d841558952bc, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Feb 02 03:03:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564961, encodeId=6e1f15649616f, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Feb 02 03:03:00 CST 2019, time=2019-02-02, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1820058, encodeId=cb11182005884, content=<a href='/topic/show?id=f073100199b2' target=_blank style='color:#2F92EE;'>#预后表征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100199, encryptionId=f073100199b2, topicName=预后表征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e2c339, createdName=by2009, createdTime=Thu Nov 07 13:03:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680594, encodeId=b9e91680594e1, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Sep 16 18:03:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1790323, encodeId=d0481e9032378, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sun Mar 17 02:03:00 CST 2019, time=2019-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425947, encodeId=fc27142594e1a, content=<a href='/topic/show?id=588988285e6' target=_blank style='color:#2F92EE;'>#葡萄膜黑色素瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88285, encryptionId=588988285e6, topicName=葡萄膜黑色素瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Feb 02 03:03:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558952, encodeId=2d841558952bc, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Feb 02 03:03:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564961, encodeId=6e1f15649616f, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Feb 02 03:03:00 CST 2019, time=2019-02-02, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1820058, encodeId=cb11182005884, content=<a href='/topic/show?id=f073100199b2' target=_blank style='color:#2F92EE;'>#预后表征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100199, encryptionId=f073100199b2, topicName=预后表征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e2c339, createdName=by2009, createdTime=Thu Nov 07 13:03:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680594, encodeId=b9e91680594e1, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Sep 16 18:03:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1790323, encodeId=d0481e9032378, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sun Mar 17 02:03:00 CST 2019, time=2019-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425947, encodeId=fc27142594e1a, content=<a href='/topic/show?id=588988285e6' target=_blank style='color:#2F92EE;'>#葡萄膜黑色素瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88285, encryptionId=588988285e6, topicName=葡萄膜黑色素瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Feb 02 03:03:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558952, encodeId=2d841558952bc, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Feb 02 03:03:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564961, encodeId=6e1f15649616f, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Feb 02 03:03:00 CST 2019, time=2019-02-02, status=1, ipAttribution=)]

相关资讯

Stem cells:沉默Aldefluor+ 乳腺CSCs的TAP1的表达有助于肿瘤细胞免疫逃逸

逃逸细胞免疫细胞的检测和破坏是肿瘤发生和进展的关键。癌干细胞(CSCs)在肿瘤发生中的重要作用已得到明确,但其逃逸免疫检测和靶向的能力尚未完全了解。在探究乳腺CSCs逃逸免疫检测的能力的过程中,Mohammad Sultan等人基于醛脱氢酶活性增强在一个自发性小鼠乳腺瘤中鉴别出一钟高度致瘤的分子。研究人员在免疫强化和免疫缺陷的小鼠中进行肿瘤生长研究。在免疫强化的小鼠中,自发性乳腺肿瘤的生长受到抑制

PLOS BIOL:耶鲁严钦组报道调控肿瘤免疫逃逸的表观遗传新机制

在机体正常细胞发展为癌细胞的过程中积累许多变化,导致癌细胞通常具有比较强的免疫原性。人体的各种先天性与获得性免疫机制可以识别这些非正常的细胞,从而在癌发展的早期将其清除,避免癌症的发生。只有通过一定的机制逃避了这些抗癌的免疫反应,癌才得以形成。这一过程被称为肿瘤的免疫逃逸。近十年来,癌细胞的免疫逃逸机制,以及针对这些机制的免疫再激活策略成为癌症新疗法的研究重点。例如最近非常热的免疫检验点疗法,就是

CLIN CANCER RES:PD-L1表达与黑色素瘤免疫逃逸

CLIN CANCER RES近期发表了一篇文章,研究接受靶向MAPK抑制剂治疗的黑色素瘤治疗前和治疗汇总的免疫活性、PD-L1表达和肿瘤信号情况。

Cell Syst:什么?癌症免疫疗效提高数倍!只需诱导脱发基因表达!

近来,哥伦比亚大学欧文医学中心(CUIMC)的研究人员进行的一项新的小鼠实验的研究表明,一种与自身免疫性脱发相关的基因可被用于改善癌症免疫治疗。该论文在《Cell Systems》杂志上发表。

Blood:T细胞耗竭导致干细胞移植后骨髓瘤细胞免疫逃逸

自体干细胞移植(auto-SCT)仍是多发性骨髓瘤(MM)的标准疗法,可延长患者的无进展存活期。一小部分患者可获得长期的病情控制,但大部分患者最终还是会复发,而复发的潜在机制尚不明确。Simone A. Minnie等人采用自体SCT治疗骨髓瘤的预临床模型,其病情或进展(MM复发)或得到控制。在骨髓中(BM),CD8+T细胞上表达的抑制受体与骨髓瘤移植后的进展密切相关。与此相一致,其共刺激/黏附受

Blood:AML激活AHR通路干扰NK细胞发育并破坏其功能,进一步实现免疫逃逸

中心点:AML的AHR通路激活,可调控miR-29b的表达,干扰NK细胞发育、影响其功能。AHR拮抗剂可逆转AML诱导的NK细胞发育障碍及其功能损伤。摘要:急性髓系白血病(AML)可通过抑制自然杀伤细胞(NK)的发育及其细胞功能,进而逃避小鼠和人类的固有免疫系统。这在一定程度上是通过过表达AML患者NK细胞的microRNA(miR)-29b来实现的,但其潜在机制尚不清楚。Steven D. Sc